RxDoctor Payments Data

Rahul Sonone, MD

Neurology · Germatown, TNNPI 1881815801

Payments from drug & device makers

$24,811in general payments, 2019–2025

Across 1,432 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novartis$2K
  • UCB, Inc.$1K
  • EMD Serono, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AstraZeneca$990
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$3,20213%
  • Food & beverage$21,40886%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)197$5,288
Novartis136$1,757
UCB, Inc.52$1,188
EMD Serono, Inc.85$1,112
Teva Pharmaceuticals USA, Inc.63$1,017
AstraZeneca(2 entities)45$990
Amgen(2 entities)56$974
Acadia Pharmaceuticals Inc65$823
Bristol Myers Squibb46$787
Pfizer85$784
Biogen42$772
Argenx US, Inc.31$765
SK Life Science, Inc.37$703
Sunovion Pharmaceuticals Inc.41$627
Amneal Pharmaceuticals LLC35$580
Neurocrine Biosciences, Inc.26$570
Genentech USA, Inc.25$442
Lundbeck LLC23$422
Lilly USA, LLC27$419
Supernus Pharmaceuticals, Inc.45$403
Biohaven Pharmaceuticals, Inc.38$349
Biohaven Pharmaceutical Holding Company Ltd.33$348
Sanofi14$306
TG Therapeutics, Inc.11$259
Johnson & Johnson(2 entities)14$222
MDD US Operations, LLC15$213
Eisai Inc.10$173
Harmony Biosciences LLC7$172
Ipsen Biopharmaceuticals, Inc8$172
Avanir Pharmaceuticals, Inc.8$160
Alnylam Pharmaceuticals Inc.9$156
Jazz Pharmaceuticals Inc.6$134
Neurelis, Inc.8$127
Otsuka America Pharmaceutical, Inc.5$113
CSL Behring6$110
Acorda Therapeutics, Inc7$107
Upsher-smith Laboratories LLC4$98
C2n Diagnostics, LLC5$96
E.r. Squibb & Sons, L.L.C.5$90
Kyowa Kirin, Inc.5$78
Axsome Therapeutics, Inc.3$76
Sumitomo Pharma America, Inc.6$64
Vanda Pharmaceuticals Inc.2$64
Greenwich Biosciences, Inc.4$64
Nevro Corp.4$63
Catalyst Pharmaceuticals, Inc.3$54
GE HealthCare3$52
Merz Pharmaceuticals, LLC2$52
Takeda Pharmaceuticals U.S.A., Inc.2$47
Aquestive Therapeutics, Inc.3$43
Tanabe Pharma America, Inc.2$40
Grifols USA, LLC2$33
Corium, LLC2$30
Adamas Pharmaceuticals, Inc.2$29
Cycle Pharmaceuticals Inc2$28
NS Pharma, Inc.1$25
Scilex Pharmaceuticals Inc.1$24
Livanova USA, Inc.1$21
Shire North American Group Inc1$16
W. L. Gore & Associates, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,811 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$119,718
Medicare patients
389
Services billed
4,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate54$268,960
Kesimpta PenOfatumumab17$165,137
AptiomEslicarbazepine Acetate27$63,496
UbrelvyUbrogepant35$41,453
BriviactBrivaracetam21$39,398
Aimovig AutoinjectorErenumab-Aooe42$31,734
BotoxOnabotulinumtoxina20$30,076
Nurtec OdtRimegepant Sulfate13$26,587
FycompaPerampanel20$23,581
RytaryCarbidopa/Levodopa14$20,633
XcopriCenobamate12$14,461
Levetiracetam250$7,665
Lamotrigine ErLamotrigine20$5,694
Lacosamide64$5,189
Oxcarbazepine56$4,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$823$268,96054 claims
AbbVieUbrelvy, Botox$5,288$71,52955 claims
Sunovion Pharmaceuticals Inc.Aptiom$627$63,49627 claims
UCB, Inc.Briviact$1,188$39,39821 claims
PfizerNurtec Odt$784$26,58713 claims
Eisai Inc.Fycompa$173$23,58120 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$580$21,52638 claims
SK Life Science, Inc.Xcopri$703$14,46112 claims
Upsher-smith Laboratories LLCTopiramate$98$1,283112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Germatown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →